

# L.D. Collins & Co. Ltd. Methodological Note (2020)

## LIST OF ABBREVIATIONS

ABPI	Association of the British Pharmaceutical Industry
GDPR	General Data Protection Regulation
HCO	Healthcare Organisation
HCP	Healthcare professional
LDC	L.D. Collins & Co. Ltd
ORDM	Other relevant decision maker
R&D	Research and Development
TOV	Transfer of value

## INTRODUCTION

L.D. Collins & Co. Ltd. is a pharmaceutical company specialising in the area of women's health. To conduct its business, L.D. Collins engages legitimately with healthcare professionals (HCPs), other relevant decision makers (ORDMs) and healthcare organisations (HCOs). Depending on the activity provided or received, a direct or indirect transfer of value (TOV) may be attached.

The Association of British Pharmaceutical Industry (ABPI) Code of Practice requires that pharmaceutical companies document and publicly disclose certain TOVs made directly or indirectly to HCPs, ORDMs and HCOs. A TOV is defined as a direct or indirect transfer of value, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines.

L.D. Collins is committed to disclosing all TOVs to HCPs, ORDMs and HCOs in accordance with its commitment to the ABPI Code of Practice.

Each company providing TOVs is required to publish a note summarising the methodologies used by the company in preparing the disclosures, identifying each category of TOV. This document summarises the methodology for the reporting period 1<sup>st</sup> January 2020 to 31<sup>st</sup> December 2020. This disclosure report is available for a period of at least three years after its disclosure and its relevant records will be retained for a period of at least five years after the end of the calendar year to which they relate.

## DEFINITIONS

**Healthcare professionals (HCPs)** are members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

**Other Relevant Decision Maker (ORDM)** particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.

**Healthcare organisations (HCO)** are either a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in Europe or an organisation through which one or more healthcare professionals or other relevant decision makers provide services.

**Transfer of value (TOV)** means a direct or indirect transfer of value, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines. A direct transfer of value is one made directly by a company for the benefit of a recipient. An indirect transfer of value is one made on behalf of a company for the benefit of a recipient or through an intermediate and where the company knows or can identify the recipient that will benefit from the transfer of value.

## METHODOLOGY

The terminology for various types of TOV is consistent with the meaning of those transactions as defined in the ABPI Code. All TOVs made by LDC to HCOs, HCPs and ORDMs in the UK between January 1<sup>st</sup> and December 31<sup>st</sup> 2020 (see section on “Date of Payment”) and corresponding to one of the categories described in the ABPI Code, were disclosed by LDC.

### Joint working

LDC was not involved in any joint working in 2020.

### Donations, grants and benefits in kind to HCOs

LDC did not give any donations, grants or benefits in kind to HCOs in 2020.

### Sponsorship of attendance by HCPs and ORDMs at meetings

LDC did not sponsor attendance by HCPs and ORDMs at meetings in 2020.

### Fees and expenses paid to HCPs and ORDMs, or to their employer on their behalf

LDC contracted a number of HCPs during the course of 2020 to provide one or more of the following services:

- a) Speaker;
- b) Chairperson;
- c) Training;
- d) Advisory Board; and
- e) Consultancy Services.

Contribution towards the costs of meetings paid to HCOs or to third parties managing events on their behalf, which may include sponsorship of HCPs or ORDMs by way of registration fees/travel & accommodation

LDC did not contribute towards the costs of any meetings in 2020.

### Research & Development (R&D)

R&D TOVs will be disclosed in an aggregate form in line with the ABPI's requirements and include:

- a) Direct and indirect payments (via a Clinical Research Organisation) related to clinical studies, including:
  - i. LDC sponsored studies (interventional and non-interventional studies); and
  - ii. Investigator sponsored studies ("ISS") (interventional and non-interventional studies)
- b) Drug supplied free of charge to a HCO for their use in an ISS. Please note that drugs supplied to HCOs are valued for disclosure purposes at the NHS list price in 2020.

### Other considerations

#### Consent for Disclosure

LDC obtained consent from HCPs in a separate consent form to the agreement in order to comply with GDPR. Where consent for disclosure was not given or unable to be obtained, these payments have been submitted in the aggregate pool.

#### Date of Transfer of Value

There is an inevitable delay between the date on which a payment is submitted and approved within LDC and the date on which the payment is made. LDC discloses the details of the payment as the date on which the transfer was completed, meaning the date that the payment is released from LDC's bank. This may mean that some projects/activities taking place at the end of one year are disclosed in the following year, because the payment may not occur until January when the invoice has been received and settled.

For non-financial TOV, such as services or benefits in kind, the date of TOV for disclosure purposes is the date on which the agreement to provide this was signed.

### MULTI-YEAR CONTRACTS

Separate TOVs for the same activity that are deemed to occur in different reporting periods will be disclosed in the applicable years as defined in "Date of Transfer of Value". No accruals will be made for Disclosure purposes.

### VAT

Where payments were made and VAT was applicable, the VAT has been excluded for the purposes of Disclosure. Therefore, all values provided are exclusive of VAT. There are no other tax considerations.

### CO-PROMOTION

If LDC has made the TOV and it is within our accounting tool, the total TOV will be included within the Disclosure Report. If the TOV was made by the co-promotion partner and subsequently charged to LDC, the part payment from LDC will be disclosed.

TOVs made by a co-promotion partner should be included in their Disclosure Report.